Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma

TAKASHI KATO, TARO OSHIKIRI, HIRONOBU GOTO, RYUICHIRO SAWADA, HITOSHI HARADA, NAOKI URAKAWA, HIROSHI HASEGAWA, SHINGO KANAJI, KIMIHIRO YAMASHITA, TAKERU MATSUDA and YOSHIHIRO KAKEJI
Anticancer Research May 2022, 42 (5) 2775-2782; DOI: https://doi.org/10.21873/anticanres.15757
TAKASHI KATO
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TARO OSHIKIRI
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: oshikiri@med.kobe-u.ac.jp
HIRONOBU GOTO
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYUICHIRO SAWADA
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HITOSHI HARADA
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOKI URAKAWA
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI HASEGAWA
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINGO KANAJI
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIMIHIRO YAMASHITA
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKERU MATSUDA
2Division of Minimally Invasive Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO KAKEJI
1Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Esophageal squamous cell carcinoma (ESCC) is a deadly malignant disease. This study examined whether the platelet-to-lymphocyte ratio (PLR) can be used as a biomarker to evaluate prognosis in patients with advanced ESCC following neoadjuvant chemotherapy (NAC) and undergoing minimally invasive esophagectomy (MIE). Patients and Methods: We examined 174 patients between January 2010 and December 2015 at the Kobe University. Of these, 121 were treated with NAC. The PLR cutoff was determined through receiver-operating characteristic curve analysis. Univariate and multivariate analyses were conducted to identify prognostic factors for overall survival (OS). Results: The PLR cutoff for OS in 121 patients was 169.6. Patients with PLR ≥169.6 had worse 5-year OS rates (31.1%) than those with a PLR <169.6 (61.1%, p=0.001). Multivariate analysis revealed that a PLR of ≥169.6 was an independent factor for poor prognosis. Conclusion: PLR is an independent prognostic factor for patients with ESCC after NAC and MIE.

Key Words:
  • Biomarker
  • esophageal squamous cell carcinoma
  • platelet-to-lymphocyte ratio
  • Received January 12, 2022.
  • Revision received March 16, 2022.
  • Accepted March 23, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (5)
Anticancer Research
Vol. 42, Issue 5
May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma
TAKASHI KATO, TARO OSHIKIRI, HIRONOBU GOTO, RYUICHIRO SAWADA, HITOSHI HARADA, NAOKI URAKAWA, HIROSHI HASEGAWA, SHINGO KANAJI, KIMIHIRO YAMASHITA, TAKERU MATSUDA, YOSHIHIRO KAKEJI
Anticancer Research May 2022, 42 (5) 2775-2782; DOI: 10.21873/anticanres.15757

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma
TAKASHI KATO, TARO OSHIKIRI, HIRONOBU GOTO, RYUICHIRO SAWADA, HITOSHI HARADA, NAOKI URAKAWA, HIROSHI HASEGAWA, SHINGO KANAJI, KIMIHIRO YAMASHITA, TAKERU MATSUDA, YOSHIHIRO KAKEJI
Anticancer Research May 2022, 42 (5) 2775-2782; DOI: 10.21873/anticanres.15757
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
  • Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
  • Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • Biomarker
  • esophageal squamous cell carcinoma
  • platelet-to-lymphocyte ratio
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire